All In Biotech

Drug Trial Radar · NCT05567796

A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose Weight

Efficacy and Safety of Cagrilintide s.c. 2.4 Milligram (mg) in Combination With Semaglutide Subcutaneous (s.c). 2.4 mg (CagriSema s.c. 2.4 mg/2.4 mg) Once-weekly in Participants With Overweight or Obesity

Last checked: Nov 19, 2026Latest source record: Sep 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 3,400 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

3,400

Planned (sponsor's estimate)

Start

Nov 1, 2022

Primary completion

Oct 30, 2024

Study completion Oct 19, 2026

Sponsor

Lead sponsor
Novo Nordisk A/SNovo Nordisk (NVO)
Sponsor type
Industry
First posted
Oct 5, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study has 2 parts: First part is the main study and second part is the extension study. During the main study participants will receive 1 of 4 study medicines. If participants continue in the extension study, they will not receive any study medicine during the extension. The main study will look at how well CagriSema helps participants with excess body weight lose weight compared to a "dummy" medicine and 2 other medicines, cagrilintide and semaglutide. Participants will either get CagriSema, cagrilintide,semaglutide or "dummy" medicine. Which treatment participants get is decided by chance. They will take one injection once a week. The study medicine is injected briefly with a thin needle, typically in the stomach, thighs or upper arms. Extension study: After the main study, not all participants will continue in the extension study. The study staff will tell the participant if they will continue or not into the extension study. In the extension study we will look at what happens to the participant's body weight and diseases related to excess body weight after the participant stops taking the study medicine. The main study will last for about 1½ years and the extension study will last for another 2 years.

Conditions

  • Obesity

Interventions

  • CagrilintideDrug

    Cagrilintide will be administered subcutaneously.

  • SemaglutideDrug

    Participants will recieve semaglutide subcutaneously.

  • Placebo cagrilintideDrug

    Participants will receive placebo matched to cagrilintide.

  • Placebo semaglutideDrug

    Participants will receive placebo matched to semaglutide.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. CagriSema versus placebo: Relative change in body weightTime frame: From baseline (week 0) to end of treatment (week 68)
  2. CagriSema versus placebo: Achievement of greater than or equal to (>=) 5% weight reductionTime frame: From baseline (week 0) to end of treatment (week 68)

Locations

256 sites in 23 countries. Site status is shown where the registry gives one.

  • Univ of Alabama Birmingham

    Birmingham, Alabama

  • Velocity Clin Res Los Angeles

    Los Angeles, California

  • Velocity Clin Res Wstlke

    Los Angeles, California

  • Univ of Colorado at Denver

    Aurora, Colorado

  • OptumCare Clinical Trials LLC

    Golden, Colorado

  • Northeast Research Institute

    Fleming Island, Florida

  • South Broward Research LLC

    Miramar, Florida

  • Clinical Neuroscience Solution

    Orlando, Florida

  • Florida Inst For Clin Res

    Orlando, Florida

  • Florida Institute for Clinical research

    Orlando, Florida

  • Clinical Trial Res Assoc,Inc

    Plantation, Florida

  • Hope Clin Res & Wellness

    Conyers, Georgia

  • East West Med Res Inst

    Honolulu, Hawaii

  • Great Lakes Clinical Trials

    Chicago, Illinois

  • Endeavor Health

    Skokie, Illinois

  • Evanston Premier Hlthcr Res

    Skokie, Illinois

  • Midwest Inst For Clin Res

    Indianapolis, Indiana

  • Northern Pines Hlth Ctr, PC

    Buckley, Michigan

  • StudyMetrix Research LLC

    City of Saint Peters, Missouri

  • Velocity Clinical Research Binghamton

    Binghamton, New York

  • Comprehensive Weight Ctrl Prog

    New York, New York

  • University of North Carolina

    Chapel Hill, North Carolina

  • University of North Carolina

    Chapel Hill, North Carolina

  • Medication Mgmnt, LLC_Grnsboro

    Greensboro, North Carolina

  • PharmQuest Life Sciences LLC

    Greensboro, North Carolina

  • Accellacare_NC

    Raleigh, North Carolina

  • Accellacare

    Wilmington, North Carolina

  • New Venture Medical Research

    Wadsworth, Ohio

  • Lynn Institute of Norman

    Norman, Oklahoma

  • The University of Penn Center

    Philadelphia, Pennsylvania

  • Clinical Res Collaborative

    Cumberland, Rhode Island

  • Medical Uni of SC Charleston

    Charleston, South Carolina

  • Coastal Carolina Res Ctr

    North Charleston, South Carolina

  • Hillcrest Clinical Research

    Simpsonville, South Carolina

  • Spartanburg Medical Research

    Spartanburg, South Carolina

  • Holston Medical Group_Bristol

    Bristol, Tennessee

  • Holston Medical Group

    Kingsport, Tennessee

  • Baylr Sctt White Rs Inst, Endo

    Dallas, Texas

  • Velocity Clinical Res-Dallas

    Dallas, Texas

  • UT Southwestern Med Cntr

    Dallas, Texas

Showing 40 of 256 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.